Posted by Michael Wonder on 24 Nov 2020
Rigel and Medison announce Health Canada approval of Tavalisse, an oral medication for the treatment of adults with chronic immune thrombocytopenia
23 November 2020 - Rigel Pharmaceuticals and Medison Pharma today announced that Health Canada has approved the new drug submission for Tavalisse (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to other treatments.
With the approval from Health Canada, Medison intends to launch Tavalisse in Canada in Q1 2021.
